ArticleBiomolecules2022
Secretory Leucoprotease Inhibitor (SLPI) Promotes Survival during Acute
Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Redox protection by bacterial glutathione peroxidase drives virulence inRedox report : communications in free radical research · 2026Article
- miR-361-5p regulates acute infective endocarditis by mediating SLPI/NF-κB signaling pathway.Cytotechnology · 2025Article
- The Role ofBiomolecules · 2025Review
- Candidate target genes in sepsis diagnosis and therapy: identifying hub genes with a spotlight on KLRB1.BMC infectious diseases · 2025Article
- Investigation of the Significance of Blood Signatures on Sepsis-Induced Acute Lung Injury in Sepsis Within 24 Hours.International journal of genomics · 2025Article
- Endogenous SLPI contributes to the regulation of inflammatory responses in peritoneal macrophages by modulating MMP-9 production.Frontiers in immunology · 2025Article
- Secretory leukocyte protease inhibitor protects against severe urinary tract infection in mice.mBio · 2024Article
- SLPI deficiency alters airway protease activity and induces cell recruitment in a model of muco-obstructive lung disease.Frontiers in immunology · 2024Article
- Secretory Leukocyte Protease Inhibitor Protects Against Severe Urinary Tract Infection in Mice.bioRxiv : the preprint server for biology · 2023Article
- Research Progress of Macromolecules in the Prevention and Treatment of Sepsis.International journal of molecular sciences · 2023Review
- Biologically Relevant Murine Models of ChronicPathogens (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secretory leucoprotease inhibitor (SLPI) has multifaceted functions, including inhibition of protease activity, antimicrobial functions, and anti-inflammatory properties. In this study, we show that SLPI plays a role in controlling pulmonary
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.